Resumen

El remdesivir para tratar la COVID-19: una revisión Cochrane

Kelly Ansems1, Felicitas Grundeis2, Karolina Dahms1, Agata Mikolajewska3, Volker Thieme2, Vanessa Piechotta4, Maria-Inti Metzendorf5, Miriam Stegemann3, Carina Benstoem1, Falk Fichtner1

Filiación de los autores

1Department of Intensive Care Medicine, Medical Faculty, RWTH Aachen University, Aachen, Alemania. 2Department of Anaesthesiology and Intensive Care, University of Leipzig Medical Center, Leipzig, Alemania. 3Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Alemania. 4Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Alemania. 5Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Alemania.

DOI

Cita

Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, et al. El remdesivir para tratar la COVID-19: una revisión Cochrane. Emergencias. 2023;35:465-7

Más artículos de los autores